A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of recombinant humanized PD-L1/4-1BB bispecific antibody (ES101) in patients with advanced solid tumors.

Timeline

Start

2019-06-28

Primary completion

2022-04-22

Completion

2022-04-22

Outcome

Outcome not reported

Stopped (Business): “Sponsor's clinical development strategy adjustment”

Drugs

Indications